Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100PLL7
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥7.8bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥4.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥4.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥3.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.8bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥3.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥51.3bnat 2022-09-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥28.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥26.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥25.2bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.2bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.2bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.6bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.7bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥19.252021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.132021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.122021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio89.4%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 13
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 629
ItemContextValueUnit
Research and development expenses IFRSPrior1YTDDuration1084170000JPY
Research and development expenses IFRSCurrentYTDDuration1888515000JPY
Other income IFRSPrior1YTDDuration29054000JPY
Other income IFRSCurrentYTDDuration5694000JPY
Other expenses IFRSPrior1YTDDuration179000JPY
Other expenses IFRSCurrentYTDDuration8776000JPY
Operating profit loss IFRSPrior1YTDDuration4034163000JPY
Operating profit loss IFRSCurrentYTDDuration-426772000JPY
Finance income IFRSPrior1YTDDuration274006000JPY
Finance income IFRSCurrentYTDDuration320426000JPY
Finance costs IFRSPrior1YTDDuration－JPY
Finance costs IFRSCurrentYTDDuration129168000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-466910000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-132986000JPY
Profit loss before tax IFRSPrior1YTDDuration3841258000JPY
Profit loss before tax IFRSCurrentYTDDuration-368500000JPY
Income tax expense IFRSPrior1YTDDuration1365454000JPY
Income tax expense IFRSCurrentYTDDuration-181896000JPY
Profit loss IFRSPrior1YTDDuration2475803000JPY
Profit loss IFRSCurrentYTDDuration-186603000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration2475803000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration-186603000JPY
Profit loss IFRSPrior1YTDDuration2475803000JPY
Profit loss IFRSCurrentYTDDuration-186603000JPY
Basic earnings loss per share IFRSPrior1YTDDuration19.25
Basic earnings loss per share IFRSCurrentYTDDuration-1.44
Diluted earnings loss per share IFRSPrior1YTDDuration19.06
Diluted earnings loss per share IFRSCurrentYTDDuration-1.44
Revenue IFRSPrior1QuarterDuration4902395000JPY
Revenue IFRSCurrentQuarterDuration6184143000JPY
Cost of sales IFRSPrior1QuarterDuration721885000JPY
Cost of sales IFRSCurrentQuarterDuration2577125000JPY
Gross profit IFRSPrior1QuarterDuration4180510000JPY
Gross profit IFRSCurrentQuarterDuration3607017000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration269314000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration1642922000JPY
Research and development expenses IFRSPrior1QuarterDuration313264000JPY
Research and development expenses IFRSCurrentQuarterDuration724797000JPY
Other income IFRSPrior1QuarterDuration－JPY
Other income IFRSCurrentQuarterDuration5175000JPY
Other expenses IFRSPrior1QuarterDuration－JPY
Other expenses IFRSCurrentQuarterDuration5549000JPY
Operating profit loss IFRSPrior1QuarterDuration3597932000JPY
Operating profit loss IFRSCurrentQuarterDuration1238924000JPY
Finance income IFRSPrior1QuarterDuration38492000JPY
Finance income IFRSCurrentQuarterDuration69626000JPY
Finance costs IFRSPrior1QuarterDuration－JPY
Finance costs IFRSCurrentQuarterDuration63063000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration-107343000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration-23014000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass